78950-82-0

Usage

Uses

Used in Pharmaceutical Industry:
rac-5,6,7,8-Tetrahydro-6-(propylamino)-1-naphthalenol is used as an intermediate compound for the production of antiparkinson medications. Its chemical structure allows it to be a key component in the synthesis of drugs that target and alleviate the symptoms of Parkinson's disease, providing relief and improved quality of life for patients suffering from this neurodegenerative disorder.

Upstream product

• 78598-91-1 2-(N-propylamino)-5-methoxytetraline 
• 32940-15-1 5-methoxy-2-tetralone 

Downstream Products

• 87857-27-0 2-(N-phenethyl-N-propylamino)-5-hydroxytetralin 
• 101403-07-0 6-[(3-Phenyl-propyl)-propyl-amino]-5,6,7,8-tetrahydro-naphthalen-1-ol 
• 1222074-04-5 (S)-(-)-2-(N-propylamino)-5-hydroxytetraline (-)-N-(3,5-dinitrobenzoyl)-α-phenylglycine salt 
• 101470-23-9 Desthienyl-Rotigotine 
• 99755-59-6 rotigotine 
• 92206-54-7 5-hydroxy-2-(N-n-propyl-N-2-[2-thienyl]ethylamino)tetralin 
• 112835-48-0 (+)-N 0437 

Relevant academic research and scientific papers

Further structure-activity relationships study of hybrid 7-{[2-(4-phenylpiperazin-1-yl)ethyl]propylamino}-5,6,7,8-tetrahydronaphthalen-2- ol analogues: identification of a high-affinity D3-preferring agonist with potent in vivo activity with long duration

This paper describes an extended structure-activity relationships study of aminotetralin-piperazine-based hybrid molecules developed earlier for dopamine D2/D3 receptors. Various analogues as positional isomers have been developed where location of the ph

Affinity for dopamine D2, D3, and D4 receptors of 2-aminotetralins. Relevance of D2 agonist binding for determination of receptor subtype selectivity.

A series of 2-aminotetralins, substituted with a methoxy or a hydroxy group on the 5- or 7-position, and with varying N-alkyl or N-arylalkyl substituents, were prepared and evaluated in binding assays for human dopamine (DA) D2, D3, and D4 receptors. Some members of this series were prepared in former studies, but were never tested in vitro with single receptor subtypes, and these were examined again. None of the tested 2-aminotetralins showed high affinity for the dopamine D4 receptor. However, a number of the 2-aminotetralins showed high affinity for both the D2 and the D3 DA receptors, as exemplified by compounds 11-15 and 21-26, while some had a reasonable selectivity for the DA D3 receptors. The affinities of the 2-aminotetralins for the D21, receptor depended on the type of radioligand (agonist or antagonist) used. The agonist affinity data, obtained by using the agonist ligand [3H]N-0437, are thought to be more relevant for calculating DA receptor subtype selectivity.